Citations

Clear

3314 citation(s) found for "Do, Alexander".

Abstract 17041: Increased Transvalvular Gradients Precede Clinical Diagnosis of Bioprosthetic Valve Thrombosis
Petrescu, Ioana, Connolly, Heidi M. , Egbe, Alexander C. , Ionescu, Filip , Nkomo, Vuyisile T. , Pellikka, Patricia A. , Pislaru, Sorin V.

Mayo Clinic

Circulation | July 2, 2021 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.17041 Get It

Introduction: Bioprosthetic valve thrombosis (BPVT) is increasingly being recognized as a cause of prosthetic valve dysfunction within the first years after surgical implantation. However, in the absence of changes in clinical status, current guidelines recommend cardiac imaging only after 10 years post bioprosthetic valve implantation . Hypothesis: We hypothesized that an increase in prosthetic valve gradient is detectable months before a formal diagnosis of symptomatic BPVT. Methods: Eighty-three patients diagnosed with BPVT and treated medically at our institution between 2002 and 2017 were retrospectively identified. Transvalvular gradients recorded on TTE immediately post implantation, at time of clinical BPVT diagnosis, and within a 12-month period prior to BPVT diagnosis were available in 45 patients: 18 for the aortic position, 11 for mitral, and 16 for tricuspid. When more than one study was conducted in the 12 months’ timeframe, the latest value was used in the analysis. Data are reported as mean (95% CI). Results: For all valve positions, an increased gradient was detectable within 12 months prior to formal BPVT diagnosis: mean increase vs. baseline of 17 (10-23) mmHg, p < 0.0001 for aortic prostheses; 5 (2-8) mmHg, p = 0.004 for mitral prostheses, and 2 mm Hg (1-3) mmHg, p = 0.003 for tricuspid prostheses. The figure presents the evolution of prosthetic valve gradients (normalized to the baseline, immediately post-implantation value) in patients with aortic (left), mitral (middle), and tricuspid (right) valve . Conclusions: Elevated gradients precede formal clinical diagnosis of BPVT. Closer monitoring of transvalvular gradients may prove useful for BPVT diagnosis before patients become symptomatic. With recent evidence supporting the efficacy of anticoagulant therapy in BPVT, earlier diagnosis may lead to an increased rate of response and better clinical outcomes.
Abstract 208: Development of Evidence Statement curation algorithms to aid cancer variant interpretation
Sheta, Lana , Danos, Arpad , Marr, Alexander , Pema, Shahil , Lin, Wan‐Hsin , Terraf, Panieh, McMichael, Joshua F. , Saliba, Jason , Krysiak, Kilannin , Barnell, Erica K. , Grisdale, Cameron J. , Rao, Shruti , Kiwala, Susanna , Coffman, Adam , Wagner, Alex H. , Griffith, Obi L. , Griffith, Malachi

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: 208-208

10.1158/1538-7445.am2021-208 Get It

Abstract The Clinical Interpretation of Variants in Cancer (CIViC) knowledgebase (civicdb.org) is an open access, centralized hub for structured, community curated and expertly moderated relationships between genomic variants and cancer. Evidence is curated from peer-reviewed, published literature and is classified into one of five Types: Predisposing, Diagnostic, Prognostic, Predictive (therapeutic), or Functional. The robustness of the Evidence is conveyed through the assignment of Levels with the first three derived from patient studies (Validated, Clinical, Case Study), Preclinical, generated from in vivo or in vitro data, and Inferential, which describes indirect associations. Each Evidence Item requires an Evidence Statement written in the curator's own words summarizing the source's results regarding the variant's clinical impact. Collaborations with groups like ClinGen have generated a significant influx of new curators, increasing the demand for detailed principles regarding data prioritization in the Evidence Statement in order to streamline the curation process. The curation community would benefit from simpler, visual guides through the complex decisions needed to appropriately and consistently curate Evidence Items. We are devoting significant effort to continue the development of straightforward Evidence curation algorithms (decision trees) similar to those used in clinical molecular testing labs to aid CIViC curators. Previously published guidelines on development of these statements are the basis of our Evidence algorithms. Obvious inflection points for curators are clearly identified with specific details noted for each to optimize decision efficiency. As the predominant Evidence Type comprising 57% of all CIViC submissions, 58% of referenced patient trials, and 92% of Preclinical submissions, Predictive Evidence is the initial focus of our pilot guidelines with Diagnostic and Prognostic to follow. Within the Predictive Evidence Type, clinical trials, case studies, and preclinical Levels each require vastly different Evidence Statement details and ultimately the creation of three separate, uniquely modeled algorithms. The implementation of these algorithms will assist in streamlining both curation and the expert review process. Notably, a template is not being created, as the preservation of curator style and voice is important to maintain the community feel of the database. To ensure the highest level of clarity, our team is utilizing specific novice and experienced curators to assist with the development process. As these algorithms pass the pilot phase, they are being tested as curator training tools. Ultimately, these guidelines will be used to encourage independence in curators and to enhance the Evidence already contained in CIViC. Citation Format: Jason Saliba, Lana Sheta, Kilannin Krysiak, Arpad Danos, Alex Marr, Erica Barnell, Shahil Pema, Wan-Hsin Lin, Panieh Terraf, Joshua F. McMichael, Cameron J. Grisdale, Shruti Rao, Susanna Kiwala, Adam Coffman, Alex Wagner, Obi L. Griffith, Malachi Griffith. Development of Evidence Statement curation algorithms to aid cancer variant interpretation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 208.
Abstract 1221: The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications
Adashek, Jacob J. , Andreev-Drakhlin, Alexander , Roszik, Jason , Desai, Aakash , Subbiah, Vivek

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: 1221-1221

10.1158/1538-7445.am2021-1221 Get It

Abstract Background: Activating receptor-tyrosine kinase rearranged during transfection (RET) mutations and fusions have been recognized as potent drivers of oncogenesis in multiple malignancies. Recently, highly potent and selective RET inhibitors, selpercatinib and pralsetinib have been FDA approved for RET fusion+ NSCLC and selpercatinib for RET+ thyroid cancers. Here we present a comprehensive analysis of RET alterations in pan-cancer adult malignancies. Patients and methods: 96,324 samples from 89,754 patients available from AACR Project Genie database version 8 were analyzed for the prevalence of RET fusions, mutations, and copy number alterations in diverse cancer types accessed July 21, 2020. The races of the samples within the cohort were 69,962 (72.6%) white, 5,388 (5.6%) Black, 4,909 (5.1%) Asian, 163 (0.17%) Native American, 48 (0.05%) Pacific Islander, and 15,854 (16.5%) were unknown. Results: There were 56,382 (58.5%) samples from primary tumors, 24,204 (25.1%) samples from unspecified metastasis sites, 4,798 (5.0%) from distant organ metastasis, 1,379 (1.4%) from lymph node metastasis, 1,279 (1.3%) from local recurrence, and 8,282 (8.6%) unknown. In 96,324 tumor samples there were 2,706 (2.81%) RET alterations. This included 223 (0.23%) fusions, 1,689 RET mutations found (1.75%) in 21 tumor histologies, and 794 (0.82%) RET amplifications identified; where the most abundant tissues harboring RET fusions were NSCLC (n = 121), papillary thyroid cancer (n = 53), breast cancer (n = 8) and colorectal cancer (n = 7) and the most abundant tissues harboring RET missense mutations were NSCLC (n = 355), colorectal cancer (n = 292), melanoma (n = 236), and thyroid cancer (n = 127). NSCLC samples with RET fusions had significantly co-altered KRAS, SETD2, PVRL4, EZH1, and RRAGC. Conclusions: RET fusions represent extremely rate events in multiple cancers. RET missense mutations occur in 2% of malignancies. Most RET missense variants are described as variants of unknown significance, limiting the impact of precision oncology for the majority of patients with RET alterations. Further functional characterization of RET variants is warranted because RET is highly targetable with therapeutics. Citation Format: Jacob J. Adashek, Alexander Andreev-Drakhlin, Jason Roszik, Aakash P. Desai, Vivek Subbiah. The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1221.
Characteristics of Early-Onset vs Late-Onset Colorectal Cancer
Collaborative, REACCT, Zaborowski, Alexandra , Abdile, Ahmed, Adamina, Michel , Aigner, Felix , d’Allens, Laura, Allmer, Caterina, Álvarez, Andrea, Anula, Rocío, Atallah, S. , Bach, Simon P. , Barussaud, Marie, Baušys, Augustinas , Bebington, Brendan , Beggs, Andrew D. , Bellolio, Felipe, Bennett, Melissa-Rose , Berdinskikh, Anton, Bevan, Vicki, Bislenghi, Gabriele , Bludau, Marc , Boutall, Adam , Brouwer, Nelleke P.M. , Bruns, Christiane J. , Burger, Jacobus W. A. , Бурлов, Никита , Campanelli, Michela , Capdepont, Maylis, Carvello, Michele , Chew, Hwee-Hoon, Christoforidis, Dimitri, Clark, David A. , Climent, Marta, Cologne, Kyle G. , Contreras, Tomás, Croner, Roland S. , Daniels, I. R. , Delrio, Paolo , Deutsch, Michael , D’Hoore, André , Drozdov, E. S. , Duek, Daniel, Dunlop, Malcolm G. , Edmundson, Aleksandra , Efetov, Sergey , El‐Hussuna, Alaa , Elliot, Brodie, Espín, Eloy , Faes, Seraina , Faiz, Omar , Frasson, Matteo , Figueiredo, Nuno , Forgan, Tim , Frizelle, Frank , Gadaev, Shamil, Gellona, José, Glyn, Tamara , Gong, Jianping, Barisic, Goran, Greenwood, Emma, Guren, Marianne G. , Guillon, Stephanie, Gutlic, Ida , Hanly, Ann, Hasegawa, Hirotoshi , Iversen, Lene Hjerrild , Hill, James , Hoch, Jiří, Hoffmeister, Michael , Hompes, Roel , Hurtado‐Pardo, Luis , Iaquinandi, Fabiano , Imbrasaitė, Ugnė , Jafari, Mehrenah Dorna, Kanemitsu, Yukihide , Karimuddin, Ahmer , Keller, Deborah S. , Kelly, Justin, Kennelly, Rory , Khrykov, Gleb , Kocián, Petr , Koh, Cherry , Kok, N. F. M., Knight, Katrina , Knol, Joep, Kontovounisios, Christos , Kørner, Hartwig , Kronberger, Irmgard, Kroon, Hidde M. , Kural, Said , Lakkis, Zaher , Lankov, Timur , Larson, Dave, Lázár, György , Lee, Kai-Yin , Lepistö, Anna , Loi, Lynette , Lynch, Craig, Maillou‐Martinaud, Helene, Maroli, Annalisa , Martling, Anna , Matzel, Klaus E. , Mayol, Julio , McDermott, Frank , Meurette, G. , Mitteregger, Martin , Моисеенко, А С, Monson, John R.T. , Moritani, Konosuke , Munini, Martino , Nahas, Caio Sérgio Rizkallah , Negoi, Ionuţ , Novikova, A , Ocares, Misael, Olkina, Alexandra, Oñate‐Ocaña, Luis F. , Otero, Jaime, Özen, Cihan , Pace, Ugo , Julião, Guilherme Pagin São , Panaiotti, Lidiia , Panís, Yves , Papamichael, Demetris , Uriburu, Juan C Patrón , Pera, Miguél , Perez, Rodrigo Oliva , Pfeffer, F. , Phang, P. Terry , Poškus, Tomas , Pringle, Heather , Proud, David , Raguz, Ivana , Rama, N. , Rasheed, Shahnawaz, Raval, Manoj J. , Reißfelder, Christoph , Meneses, Juan Carlos Reyes , Ris, Frédéric , Riss, Stefan , Rodríguez‐Zentner, Homero , Saklani, Avanish , Salido, Andrea Jiménez, Sammour, Tarik , Saraste, Deborah , Schneider, Martin , Seishima, Ryo , Sekulic, Aleksander , Seppälä, Toni T. , Sheahan, Kieran , Shine, Rebecca , Shlomina, Alexandra , Sica, Guiseppe S., Singnomklao, T, Siragusa, Leandro , Spinelli, Antonino , Staiger, Roxane D. , Stamos, Michael J. , Sunderland, Michael, Tan, Ker‐Kan , Tanis, Pieter J. , Tekkis, Paris, Teklay, Biniam, Tengku, Sabrina , Jiménez‐Toscano, Marta , Turina, Matthias , Ulrich, Alexis , Vailati, Bruna Borba , Harten, Meike van, Warrier, Satish K. , Wexner, Steve, Wilt, Hans De, Xynos, Evangelos , You, Nancy, Zakharenko, Alexander, Zeballos, Justino, Winter, D. C. , Wexner, Steven D. , Hoffmeister, Michael , Seppälä, Toni T , Spinelli, Antonino , Wexner, Steven D , Ris, Frederic , Collaborative, REACCT, Andric, Mihailo , Bala, Miklosh , Biondo, Sebastiano , Brown, Carl James , Buchanan, Daniel D. , Buchwald, Pamela , Dapri, Giovanni , Davies, Justin , Denost, Quentin , Dias, André Roncon , Dziki, Adam Janusz , Emile, Sameh Hany , Evans, Martyn D. , Fleming, Fergal J. , Foppa, Caterina , Fowler, G , Gong, Jianping, Greenwood, Emma, Hahnloser, Dieter , Hampel, Heather , Hill, Andrew Graham , Islam, Rumana, Jafari, Mehrenah D, Карачун, А. М. , Krivokapić, Zoran , Kryžauskas, Marius , Kusters, Miranda , Lee, Suk-Hwan , Lefèvre, Jérémie H. , Lieu, Christopher H. , Martin, Sean, Millán, Mónica , Morărașu, Ștefan , Möslein, Gabriela , Nahas, Sérgio Carlos , Okabayashi, Koji , Олькина, Александра Юрьевна , Park, Jason , Patel, Swati , Petrov, Alexei, Rega, Daniela , Roxburgh, Campbell S.D. , Smart, Neil James , Solis, Alejandro, Steele, Scott R. , Владимирович, Царьков Петр , Verhoef, Cornelis , Weinberg, Benjamin A. , Wells, Cameron I. , Wolthuis, Albert M.

Mayo Clinic

JAMA Surgery | June 30, 2021 | Volume: 156 | Issue: 9 | Pages: 865

10.1001/jamasurg.2021.2380 | PMID 34190968 Get It

Respective Roles of Craniosynostosis and Syndromic Influences on Cranial Fossa Development
Lu, Xiaona , Forte, Antonio J. , Wilson, Alexander T. , Park, Kitae Eric , Allam, Omar , Alperovich, Michael , Steinbacher, Derek M., Alonso, Nivaldo , Persing, John A. , Forte, Antonio Jorge

Mayo Clinic

Plastic & Reconstructive Surgery | June 28, 2021 | Volume: 148 | Issue: 1 | Pages: 145-156

10.1097/prs.0000000000008101 | PMID 34181610 Get It

Background: Little is known about the detailed growth of the cranial fossae, even though they provide an important structural connection between the cranial vault and the facial skeleton. This study details the morphologic development of isolated cranial vault synostosis and associated syndromes on cranial fossa development. Methods: A total of 125 computed tomographic scans were included (nonsyndromic bicoronal synostosis, n = 36; Apert syndrome associated with bicoronal synostosis, n = 24; Crouzon syndrome associated with bicoronal synostosis, n = 11; and controls, n = 54). Three-dimensional analyses were produced using Materialise software. Results: The regional anterior and middle cranial fossae volumes of nonsyndromic bicoronal synostosis are characterized by significant increases of 43 percent (p < 0.001) and 60 percent (p < 0.001), respectively, and normal posterior cranial fossa volume. The cranial fossae depths of nonsyndromic bicoronal synostosis were increased, by 37, 42, and 21 percent (all p < 0.001) for anterior, middle, and posterior cranial fossae, respectively, accompanying the shortened cranial fossae lengths. The volume and morphology of all cranial fossae in Apert syndrome nearly paralleled nonsyndromic bicoronal synostosis. However, Crouzon syndrome had reduced depths of cranial fossae, and more restricted fossa volumes than both Apert syndrome and nonsyndromic bicoronal synostosis. Conclusions: Cranial vault suture synostosis is likely to be more influential on cranial fossae development than other associated influences (genetic, morphologic) in Apert and Crouzon syndromes. Isolated Apert syndrome pathogenesis is associated with an elongation of the anterior cranial fossa length in infants, whereas in Crouzon syndrome, there is a tendency to reduce cranial fossa depth, suggesting individual adaptability in cranial fossae development related to vault synostosis.
The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial
Parlow, Simon , Santo, Pietro Di , Mathew, Rebecca , Jung, Richard G. , Gillmore, Taylor , Mao, Brennan, Abdel‐Razek, Omar , Ramirez, F. Daniel , Dick, Alexander , Glover, Christopher, Russo, Juan , Froeschl, Michael , Labinaz, Marino , Hibbert, Benjamin , investigators, the CAPITAL DOREMI, Ramirez, F Daniel , Hibbert, Benjamin , Simard, Trevor , Marbach, Jeffrey A. , Fernando, Shannon M. , investigators, the CAPITAL DOREMI

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | June 27, 2021 | Volume: 10 | Issue: 7 | Pages: 712-720

10.1093/ehjacc/zuab052 | PMID 34382063 Get It

AbstractAimsCardiogenic shock (CS) is a state of low cardiac output resulting in end-organ hypoperfusion. Despite high in-hospital mortality rates, little evidence exists regarding the optimal mean arterial pressure (MAP) target in CS. We therefore evaluated the relationship between achieved MAP and clinical outcomes in patients with CS.Methods and resultsWe performed a post hoc analysis of the CAPITAL DOREMI trial: a randomized, double-blind trial comparing dobutamine to milrinone in patients with CS. We divided patients into a high MAP group (average MAP ≥ 70 mmHg over the 36 h following randomization), and a low MAP group (average MAP &lt; 70 mmHg). Our primary outcome included in-hospital all-cause mortality, resuscitated cardiac arrest, need for cardiac transplantation or mechanical circulatory support, non-fatal myocardial infarction, transient ischaemic attack or stroke, or initiation of renal replacement therapy. In total, 71 (37.0%) patients achieved an average MAP &lt; 70 mmHg, and 121 (63.0%) achieved an average MAP ≥ 70 mmHg. The primary outcome occurred in 48 (67.6%) patients in the low MAP group and 51 (42.2%) patients in the high MAP group [adjusted relative risk (aRR) 0.70; 95% confidence interval (CI) 0.53–0.92; P = 0.01]. All-cause mortality occurred in 41 (57.8%) and 35 (28.9%) patients in the low and high MAP groups, respectively (aRR 0.56; 95% CI 0.40–0.79; P &lt; 0.01). There were no significant differences in any secondary outcomes between each group.ConclusionsIn patients with CS treated with inotrope therapy, low MAP is associated with worse clinical outcomes. Randomized data evaluating optimal MAP targets in CS is needed to guide medical therapy.
Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating—a step in the right direction for targeted treatment? Authors' reply
Nelson, Alfred D. , Black, Christopher J. , Houghton, Lesley A. , Lugo‐Fagundo, Nahyr , Lacy, Brian E. , Ford, Alexander C. , Lugo-Fagundo, Nahyr Sofía, Houghton, L A , Ford, Alexander C , Black, Christopher J

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 25, 2021 | Volume: 54 | Issue: 2 | Pages: 198-199

10.1111/apt.16443 | PMID 34170542 Get It

LINKED CONTENTThis article is linked to Nelson et al and Vasant papers. To view these articles, visit https://doi.org/10.1111/apt.16437 and https://doi.org/10.1111/apt.16440
The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome
Mohr, Sandra , Fritz, Nikola, Hammer, Christian , Martínez, Cristina , Berens, Sabrina , Schmitteckert, Stefanie , Wahl, Verena, Schmidt, Målin , Houghton, Lesley A. , Goebel‐Stengel, Miriam , Kabisch, Maria, Götze, Dorothea, Milovač, Irina , D’Amato, Mauro , Röth, Ralph , Mönnikes, Hubert, Engel, Felicitas , Gauss, Annika , Tesarz, Jonas , Raithel, Martin , Andresen, Viola , Frieling, Thomas , Pehl, Christian, Stein‐Thöringer, Christoph, Clarke, Gerard , Kennedy, Paul J. , Cryan, John F. , Spiller, Robert E. , Beltrán, Caroll J. , Madrid, Ana María , Torres, Verónica , Arce, Edith Pérez de , Herzog, Wolfgang , Sayuk, Gregory S. , Karamanolis, George, Pojskić, Lejla , Bustamante, Mariona , Rabionet, Raquel , Estivil, Xavier, Wouters, Mira M. , Rappold, Gudrun , Santos, Javier , Schaefert, Rainer , Niesler, Beate , Zheng, Tenghao , Engel, Felicitas , Gauss, Annika , Tesarz, Jonas , Raithel, Martin , Andresen, Viola , Frieling, Thomas , Keller, Jutta , Stein-Thöringer, Christoph , Clarke, Gerard , Kennedy, Paul J , Cryan, John F , Dinan, Timothy G , Quigley, Eamonn M M , Spiller, Robin , Madrid, Ana María , Pérez de Arce, Edith , Herzog, Wolfgang , Mayer, Emeran A , Sayuk, Gregory , Gazouli, Maria , Karamanolis, George , Kapur-Pojskič, Lejla , Bustamante, Mariona , Rabionet, Raquel , Estivil, Xavier , Franke, André , Lieb, Wolfgang , Boeckxstaens, Guy , Wouters, Mira M , Simrén, Magnus , Rappold, Gudrun A , Vicario, Maria , Santos, Javier , Schaefert, Rainer , Lorenzo-Bermejo, Justo , Niesler, Beate , D'Amato, Mauro , Houghton, L A , Martínez, Cristina , Zheng, Tenghao , Stein-Thöringer, Christoph K., Quigley, Eamonn M.M. , Torres, Verónica, Boeckxstaens, Guy E. , Simrén, Magnus , Bermejo, Justo Lorenzo

Mayo Clinic

Journal of Cellular and Molecular Medicine | June 24, 2021 | Volume: 25 | Issue: 16 | Pages: 8047-8061

10.1111/jcmm.16736 | PMID 34165249 Get It

AbstractIrritable bowel syndrome (IBS) is a gut‐brain disorder in which symptoms are shaped by serotonin acting centrally and peripherally. The serotonin transporter gene SLC6A4 has been implicated in IBS pathophysiology, but the underlying genetic mechanisms remain unclear. We sequenced the alternative P2 promoter driving intestinal SLC6A4 expression and identified single nucleotide polymorphisms (SNPs) that were associated with IBS in a discovery sample. Identified SNPs built different haplotypes, and the tagging SNP rs2020938 seems to associate with constipation‐predominant IBS (IBS‐C) in females. rs2020938 validation was performed in 1978 additional IBS patients and 6,038 controls from eight countries. Meta‐analysis on data from 2,175 IBS patients and 6,128 controls confirmed the association with female IBS‐C. Expression analyses revealed that the P2 promoter drives SLC6A4 expression primarily in the small intestine. Gene reporter assays showed a functional impact of SNPs in the P2 region. In silico analysis of the polymorphic promoter indicated differential expression regulation. Further follow‐up revealed that the major allele of the tagging SNP rs2020938 correlates with differential SLC6A4 expression in the jejunum and with stool consistency, indicating functional relevance. Our data consolidate rs2020938 as a functional SNP associated with IBS‐C risk in females, underlining the relevance of SLC6A4 in IBS pathogenesis.
Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells
Walter, Karolin , Rodríguez-Aznar, Eva , Ferreira, Mónica S. Ventura , Frappart, Pierre‐Olivier , Dittrich, Tabea, Tiwary, Kanishka , Meessen, Sabine, Lerma, Laura , Daiß, Nora, Schulte, Lucas-Alexander , Najafova, Zeynab , Arnold, Frank , Usachov, Valentyn , Azoitei, Ninel , Erkan, Mert , Brümmendorf, Tim H. , Seufferlein, Thomas , Kleger, Alexander , Tabarés, E. , Güneş, Çagatay , Johnsen, Steven A. , Beier, Fabian , Sáinz, Bruno , Hermann, Patrick , Brümmendorf, Tim H , Kleger, Alexander , Günes, Cagatay , Johnsen, Steven A , Beier, Fabian , Sainz, Bruno , Hermann, Patrick C , Najafova, Zeynab , Lechel, André

Mayo Clinic

Cancers | June 23, 2021 | Volume: 13 | Issue: 13 | Pages: 3145

10.3390/cancers13133145 | PMID 34201898 Get It

To assess the role of telomerase activity and telomere length in pancreatic CSCs we used different CSC enrichment methods (CD133, ALDH, sphere formation) in primary patient-derived pancreatic cancer cells. We show that CSCs have higher telomerase activity and longer telomeres than bulk tumor cells. Inhibition of telomerase activity, using genetic knockdown or pharmacological inhibitor (BIBR1532), resulted in CSC marker depletion, abrogation of sphere formation in vitro and reduced tumorigenicity in vivo. Furthermore, we identify a positive feedback loop between stemness factors (NANOG, OCT3/4, SOX2, KLF4) and telomerase, which is essential for the self-renewal of CSCs. Disruption of the balance between telomerase activity and stemness factors eliminates CSCs via induction of DNA damage and apoptosis in primary patient-derived pancreatic cancer samples, opening future perspectives to avoid CSC-driven tumor relapse. In the present study, we demonstrate that telomerase regulation is critical for the “stemness” maintenance in pancreatic CSCs and examine the effects of telomerase inhibition as a potential treatment option of pancreatic cancer. This may significantly promote our understanding of PDAC tumor biology and may result in improved treatment for pancreatic cancer patients.
Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer
Quinn, Michael C. , McCue, Karen, Shi, Wei , Johnatty, Sharon E. , Beesley, Jonathan, Civitarese, Andrew, O’Mara, Tracy A. , Glubb, Dylan M. , Armasu, Sebastian M. , Ong, Jue‐Sheng , Lu, Yi , Gao, Bo , Patch, Ann‐Marie , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, García, María J. , Goodman, Marc T. , Dörk, Thilo , Moysich, Kirsten B. , Pfisterer, Jacobus , Bauman, Klaus, Lester, Jenny , Cunningham, Julie M. , McCauley, Bryan M. , Høgdall, Claus , Schildkraut, Joellen M. , Riggan, Marjorie J. , Terry, Kathryn L. , Webb, Penelope M. , May, Taymaa, Ene, Gabrielle, Huntsman, David G., Woo, Michelle, Carney, Michael E. , Fereday, Sián , Kennedy, Catherine J. , Edwards, Stacey L. , DeFazio, Anna , Goode, Ellen L. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Lambrechts, Diether , Quinn, Michael C J , Ong, Jue-Sheng , Gharahkhani, Puya , Lu, Yi , Fasching, Peter A , Lambrechts, Diether , Vergote, Ignace , Dörk, Thilo , Dürst, Matthias , Modugno, Francesmary , Bois, Andreas du , Karlan, Beth Y , Cunningham, Julie M , Kjaer, Susanne K , Webb, Penelope M , Friedlander, Michael , Glasspool, Rosalind , Hinsley, Samantha , Heitz, Florian , Kennedy, Catherine J , Winham, Stacey J , Fazio, Anna de , Pharoah, Paul D P , MacGregor, Stuart , Lambrechts, Diether , Moysich, Kirsten , O'Mara, Tracy A , Chenevix-Trench, Georgia , Høgdall, Claus K , Fereday, Sian , Goodman, Marc T , Beesley, Jonathan, Tyrer, Jonathan P. , Gharahkhani, Puya , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Modugno, Francesmary , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Jensen, Allan , Høgdall, Estrid , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Friedländer, Michael , Pejovic, Tanja B. , Moffitt, Melissa , Glasspool, Rosalind , Heitz, Florian , Winham, Stacey J. , Pharoah, Paul D.P.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 23, 2021 | Volume: 30 | Issue: 9 | Pages: 1669-1680

10.1158/1055-9965.epi-20-1817 | PMID 34162658 Get It

Abstract Background: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance. Methods: We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy. Results: We found seven SNPs at 12q24.33 associated with PFS (P &lt; 5 × 10–8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15–1.34; P = 1.47 × 10–8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro. Conclusions: The locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association. Impact: This finding provides insight into genetic markers associated with EOC outcome and potential treatment options. See related commentary by Peres and Monteiro, p. 1604